Spots Global Cancer Trial Database for Effect of Tivantinib on the QTC Interval in Cancer Subjects
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Effect of Tivantinib on the QTC Interval in Cancer Subjects
Official Title: A PHASE 1 SINGLE-BLIND, SINGLE-SEQUENCE STUDY ASSESSING THE EFFECT OF TIVANTINIB ON THE QTC INTERVAL IN CANCER SUBJECTS
Study ID: NCT01699061
Conditions
Study Description
Brief Summary: The purpose of this study is to determine the effects of tivantinib on the QTc interval in patients with solid tumors
Detailed Description: The study is designed to estimate the maximum change in QTcF (change from baseline) between placebo and multiple-dose tivantinib. A tivantinib oral dose of 360 mg BID has been selected for this study because this is the highest dose currently being evaluated in clinical studies.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
Contact Details
Name: Hamim Zahir, BPharm, PhD
Affiliation: Daiichi Sankyo UK Ltd.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
